Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,105.20
(
-0.38%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
101.10
(
4.53%
)
Bitcoin
78,012.01
(
-0.29%
)
News Focus
News Focus
Post# of 517542
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

georgejjl

Send PM Follow Ignore
Followers 147
Posts 26194
Boards Moderated 0
Alias Born 04/08/2004

georgejjl

Re: frrol post# 436288

Saturday, 10/21/2023 4:33:31 PM

Saturday, October 21, 2023 4:33:31 PM

Post# of 517542
Blarcamesine did NOT statistically fail one of the co-primary endpoints of the Phase 2b/3 Alzheimer's trial. I challenge you to show in writing the Phase 2b/3 statistically failed co-primary.

Regarding the dose response. The 50 mg per day dose is stronger in most participants than the 30 mg per day dose,

Quit making up FACTS. FACTS are FACTS. Quit making up the FACTS.

GOD bless,
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News